FDA clears Roche’s Susvimo implant for eye disease wet AMDRoche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration Share XFDA clears Roche’s Susvimo implant for eye disease wet AMDhttps://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/
FDA OKs first biosimilar of Roche’s blockbuster AMD drug LucentisSamsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Share XFDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentishttps://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/
Europe has its first Lucentis biosimilar, Samsung Bioepis’ ByoovizNovartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission Share XEurope has its first Lucentis biosimilar, Samsung Bioepis’ Byoovizhttps://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/
Novartis says trials back Beovu safety in diabetic eye diseaseThere is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to Share XNovartis says trials back Beovu safety in diabetic eye diseasehttps://pharmaphorum.com/news/novartis-says-trials-back-beovu-safety-in-diabetic-eye-disease/
Roche eyes October decision by FDA for wet AMD implantThe FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related Share XRoche eyes October decision by FDA for wet AMD implanthttps://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/
Novartis taps smartpatient for app to support wet AMD patientsGerman digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet Share XNovartis taps smartpatient for app to support wet AMD patientshttps://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/
Novartis’ blockbuster hope Beovu clears EMA advisory panelNovartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green Share XNovartis’ blockbuster hope Beovu clears EMA advisory panelhttps://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/
MHRA says Avastin can be used for AMD despite Bayer, Novartis objectionsThe UK drugs regulator has endorsed the use of Roche’s Avastin as a treatment for age-related macular degeneration, Share XMHRA says Avastin can be used for AMD despite Bayer, Novartis objectionshttps://pharmaphorum.com/news/mhra-says-avastin-can-be-used-for-amd-despite-bayer-novartis-objections/
Novartis backs brolucizumab with new head-to-head Eylea trialNovartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Share XNovartis backs brolucizumab with new head-to-head Eylea trialhttps://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/
